keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer, prognostic markers

keyword
https://www.readbyqxmd.com/read/29775627/acquisition-of-tumorigenic-potential-and-therapeutic-resistance-in-cd133-subpopulation-of-prostate-cancer-cells-exhibiting-stem-cell-like-characteristics
#1
Rajnee Kanwal, Sanjeev Shukla, Ethan Walker, Sanjay Gupta
The role of CD133 (Prominin-1) as a cancer stem cell marker may be useful for therapeutic approaches and prognostication in prostate cancer patients. We investigated the stem-cell-related function and biological features of a subpopulation of CD133+ cells isolated from established primary human prostate cancer cell lines. The CD133+ cells sorted from human prostate cancer 22Rv1 exhibited high clonogenic and tumorigenic capabilities, sphere forming capacity and serially reinitiated transplantable tumors in NOD-SCID mice...
May 15, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29772540/hsp70-and-gama-semino-protein-as-possible-prognostic-marker-of-prostate-cancer
#2
Sanjay Kumar, Sanjeev Gurshaney, Yori Adagunodo, Erica Gage, Shezreen Qadri, Mahak Sharma, Shalie Malik, Upender Manne, Udai P Singh, Rajesh Singh, Manoj K Mishra
In the United States, Prostate Cancer (PCa) is the leading cause of cancer-related mortality in men. PCa resulted in abnormal growth and function of prostate gland such as secretion of high level of gamma-seminoprotein (gama-SM)/Prostate-Specific Antigen (PSA) which could be detected in the blood. Beside gama-SM protein, the levels of heat shock proteins (Hsp70) were also observed significantly high. Therefore, gama-SM and Hsp70 are unique proteins with high potential for PCa therapeutics and diagnostics. High level of Hsp70 suppresses apoptosis, thus allowing PCa cells to exist; however, depletion of Hsp70 induces apoptosis in PCa cells...
June 1, 2018: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/29761525/ets2-is-a-prostate-basal-cell-marker-and-is-highly-expressed-in-prostate-cancers-aberrantly-expressing-p63
#3
Alba Torres, Mohammed Alshalalfa, Elai Davicioni, Anuj Gupta, Srinivasan Yegnasubramanian, Sarah J Wheelan, Jonathan I Epstein, Angelo M De Marzo, Tamara L Lotan
BACKGROUND: Rare prostate carcinomas aberrantly express p63 and have an immunophenotype intermediate between basal and luminal cells. Here, we performed gene expression profiling on p63-expressing prostatic carcinomas and compared them to usual-type adenocarcinoma. We identify ETS2 as highly expressed in p63-expressing prostatic carcinomas and benign prostate basal cells, with lower expression in luminal cells and primary usual-type adenocarcinomas. METHODS: A total of 8 p63-expressing prostate carcinomas at radical prostatectomy were compared to 358 usual-type adenocarcinomas by gene expression profiling performed on formalin fixed paraffin embedded tumor tissue using Affymetrix 1...
May 15, 2018: Prostate
https://www.readbyqxmd.com/read/29755696/the-use-of-long-non-coding-rnas-as-prognostic-biomarkers-and-therapeutic-targets-in-prostate-cancer
#4
REVIEW
Cristian Arriaga-Canon, Inti Alberto De La Rosa-Velázquez, Rodrigo González-Barrios, Rogelio Montiel-Manríquez, Diego Oliva-Rico, Francisco Jiménez-Trejo, Carlo Cortés-González, Luis A Herrera
Prostate cancer is the most common cancer in men and the second leading cause of cancer-related deaths. The most used biomarker to detect prostate cancer is Prostate Specific Antigen (PSA), whose levels are measured in serum. However, it has been recently established that molecular markers of cancer should not be based solely on genes and proteins but should also reflect other genomic traits; long non-coding RNAs (lncRNAs) serve this purpose. lncRNAs are transcripts of >200 bases that do not encode proteins and that have been shown to display abnormal expression profiles in different types of cancer...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29741162/the-urinary-sarcosine-creatinine-ratio-is-a-potential-diagnostic-and-prognostic-marker-in-prostate-cancer
#5
Meng Wang, Lihui Zou, Jing Liang, Xin Wang, Dalei Zhang, Yuan Fang, Junhua Zhang, Fei Xiao, Ming Liu
BACKGROUND The aim of this study was to evaluate the role of the urinary sarcosine/creatinine ratio in the diagnosis and prognosis of prostate cancer, using a sarcosine oxidase assay. MATERIAL AND METHODS Urine samples were obtained from 203 patients with benign prostate hyperplasia (BPH) and 209 patients with prostate cancer. Levels of urinary sarcosine were measured using the sarcosine oxidase method. The urinary sarcosine/creatinine ratios were compared between the group of patients with BPH and the patients with prostate cancer...
May 9, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29735818/treatment-strategy-for-metastatic-prostate-cancer-with-extremely-high-psa-level-reconsidering-the-value-of-vintage-therapy
#6
Yasutaka Yamada, Shinichi Sakamoto, Yoshiyasu Amiya, Makoto Sasaki, Takayuki Shima, Akira Komiya, Noriyuki Suzuki, Koichiro Akakura, Tomohiko Ichikawa, Hiroomi Nakatsu
The prognostic significance of initial prostate-specific antigen (PSA) level for metastatic prostate cancer remains uncertain. We investigated the differences in prognosis and response to hormonal therapies of metastatic prostate cancer patients according to initial PSA levels. We analyzed 184 patients diagnosed with metastatic prostate cancer and divided them into three PSA level groups as follows: low (<100 ng ml-1 ), intermediate (100-999 ng ml-1 ), and high (≥1000 ng ml-1 ). All patients received androgen deprivation therapy (ADT) immediately...
May 4, 2018: Asian Journal of Andrology
https://www.readbyqxmd.com/read/29730475/six-transmembrane-epithelial-antigen-of-prostate-3-predicts-poor-prognosis-and-promotes-glioblastoma-growth-and-invasion
#7
Mingzhi Han, Ran Xu, Shuai Wang, Ning Yang, Shilei Ni, Qing Zhang, Yangyang Xu, Xin Zhang, Chao Zhang, Yuzhen Wei, Jianxiong Ji, Bin Huang, Di Zhang, Anjing Chen, Wenjie Li, Rolf Bjerkvig, Xingang Li, Jian Wang
Recent evidence suggests that dysregulation of iron regulatory factors may play essential roles in cancer pathophysiology. Six-transmembrane epithelial antigen of prostate 3 (STEAP3) is a metalloreductase, which is vital for cellular iron uptake and homeostasis. However, the clinical significance and function of STEAP3 in the development of human gliomas remain unclear. Through analysis of publicly available databases, we found that STEAP3 was highly expressed in malignant gliomas, especially in the mesenchymal glioma molecular subtype and isocitrate dehydrogenase 1/2 (IDH1/2) wild-type gliomas...
May 3, 2018: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/29726910/single-nucleotide-polymorphisms-of-stemness-genes-predicted-to-regulate-rna-splicing-microrna-and-oncogenic-signaling-are-associated-with-prostate-cancer-survival
#8
Jennifer A Freedman, Yanru Wang, Xuechan Li, Hongliang Liu, Patricia G Moorman, Daniel J George, Norman H Lee, Terry Hyslop, Qingyi Wei, Steven R Patierno
Prostate cancer is a clinically and molecularly heterogeneous disease, with variation in outcomes only partially predicted by grade and stage. Additional tools to distinguish indolent from aggressive disease are needed. Phenotypic characteristics of stemness correlate with poor cancer prognosis. Given this correlation, we identified single nucleotide polymorphisms (SNPs) of stemness-related genes and examined their associations with prostate cancer survival. SNPs within stemness-related genes were analyzed for association with overall survival of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial...
May 3, 2018: Carcinogenesis
https://www.readbyqxmd.com/read/29725501/the-untold-stories-of-the-speech-gene-the-foxp2-cancer-gene
#9
REVIEW
Maria Jesus Herrero, Yorick Gitton
FOXP2 encodes a transcription factor involved in speech and language acquisition. Growing evidence now suggests that dysregulated FOXP2 activity may also be instrumental in human oncogenesis, along the lines of other cardinal developmental transcription factors such as DLX5 and DLX6 [1-4]. Several FOXP familymembers are directly involved during cancer initiation, maintenance and progression in the adult [5-8]. This may comprise either a pro-oncogenic activity or a deficient tumor-suppressor role, depending upon cell types and associated signaling pathways...
January 2018: Genes & Cancer
https://www.readbyqxmd.com/read/29720147/crbp-1-over-expression-is-associated-with-poor-prognosis-in-tongue-squamous-cell-carcinoma
#10
Yue Chen, Tian Tian, Min-Jie Mao, Wei-Ye Deng, Hao Li
BACKGROUND: Tongue squamous cell carcinoma (TSCC) is one of the most common malignancies of oral squamous cell carcinomas. Cellular retinol binding protein-1 (CRBP-1) as a carrier protein transports retinol from the liver storage site to peripheral tissue. Up-regulated expression of CRBP-1 is associated with some tumor types such as prostate cancer, breast cancer and ovarian cancer as reported, but its role in TSCC remains uncertain. METHODS: In this study, an integrated bioinformatics analysis based on the multiple cancer microarray data sets available from Oncomine database was conducted to view the differential expression of CRBP-1 between TSCC and the adjacent non-tumorous tissues...
May 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29699892/primary-mutational-landscape-linked-with-pre-docetaxel-lactate-dehydrogenase-levels-predicts-docetaxel-response-in-metastatic-castrate-resistant-prostate-cancer
#11
Kenneth Hiew, Claire A Hart, Adnan Ali, Tony Elliott, Vijay Ramani, Vijay Sangar, Maurice Lau, Satish Maddineni, Mick Brown, Noel Clarke
BACKGROUND: Docetaxel chemotherapy is a standard of care for metastatic castrate-resistant prostate cancer (mCRPC): 40-50% of patients achieve a biochemical response. However, there is a lack of response predictive biomarkers. OBJECTIVE: To assess lactate dehydrogenase (LDH) as a docetaxel response biomarker in mCRPC and to examine the association of LDH with genomic alterations in primary diagnostic biopsies. DESIGN, SETTING, AND PARTICIPANTS: Clinical and associated primary tumour-targeted next-generation sequencing data from matched training (n=150) and test (n=120) cohorts of progressive mCRPC patients receiving docetaxel therapy were analysed...
April 23, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29682524/pancd44-immunohistochemical-evaluation-in-prostatectomies-from-patients-with-adenocarcinoma
#12
Carlos Gustavo Hirth, Adriele Machado Dos Santos, João Batista Gadelha de Cerqueira, Francisco Vagnaldo Fechine Jamacaru, Maria do Perpétuo Socorro Saldanha da Cunha, Conceição Aparecida Dornelas
Introduction: CD44 has been proposed as a prognostic marker and a stem cell marker but studies in patients with prostate cancer have yielded inconsistent results. Patients and Methods: Patients submitted to radical prostatectomy between 2008 and 2013 at a university hospital were followed with biannual serum PSA tests to determine the biochemical recurrence (BR). Archived paraffin blocks with neoplastic and nonneoplastic tissue were evaluated immunohistochemically for a panCD44 and MYC...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29679564/frequencies-and-expression-levels-of-programmed-death-ligand-1-pd-l1-in-circulating-tumor-rna-ctrna-in-various-cancer-types
#13
Toshiyuki Ishiba, Andreas-Claudius Hoffmann, Joshua Usher, Yahya Elshimali, Todd Sturdevant, Mai Dang, Yolanda Jaimes, Rama Tyagi, Ronald Gonzales, Mary Grino, Jacek K Pinski, Afsaneh Barzi, Luis E Raez, Wilfried E Eberhardt, Dirk Theegarten, Heinz-Josef Lenz, Hiroyuki Uetake, Peter V Danenberg, Kathleen Danenberg
BACKGROUND: Precision medicine and prediction of therapeutic response requires monitoring potential biomarkers before and after treatment. Liquid biopsies provide noninvasive prognostic markers such as circulating tumor DNA and RNA. Circulating tumor RNA (ctRNA) in blood is also used to identify mutations in genes of interest, but additionally, provides information about relative expression levels of important genes. In this study, we analyzed PD-L1 expression in ctRNA isolated from various cancer types...
April 27, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29662636/analysis-of-hematological-parameters-as-prognostic-markers-for-toxicity-and-survival-of-223-radium-treatment
#14
Asha Leisser, Marzieh Nejabat, Markus Hartenbach, Reza Agha Mohammadi Sareshgi, Shahrokh Shariat, Gero Kramer, Michael Krainer, Marcus Hacker, Alexander R Haug
223 Radium (223 Ra) has emerged as treatment prolonging survival in patients with metastatic castration-resistant prostate cancer (CRPC). As 223 Ra can cause hematotoxicity (HT), pre-existing hematopoiesis might influence the efficacy of 223 Ra and the rate of hematotoxicity, but as to our knowledge such data has not been published yet, we retrospectively conducted an analysis on patients receiving 223 Ra. 54 patients treated with 223 Ra had a median survival of 67 weeks, which was significantly reduced in patients with pre-existing Hb toxicity (Tox) grade 2 (48 weeks P = 0...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29608247/regulation-of-ncapg-by-mir-99a-3p-passenger-strand-inhibits-cancer-cell-aggressiveness-and-is-involved-in-crpc
#15
Takayuki Arai, Atsushi Okato, Yasutaka Yamada, Sho Sugawara, Akira Kurozumi, Satoko Kojima, Kazuto Yamazaki, Yukio Naya, Tomohiko Ichikawa, Naohiko Seki
Effective treatments for patients with castration-resistant prostate cancer (CRPC) have not yet been established. Novel approaches for identification of putative therapeutic targets for CRPC are needed. Analyses of RNA sequencing of microRNA (miRNA) expression revealed that miR-99a-3p (passenger strand) is significantly downregulated in several types of cancers. Here, we aimed to identify novel miR-99a-3p regulatory networks and therapeutic targets for CRPC. Ectopic expression of miR-99a-3p significantly inhibited cancer cell proliferation, migration, and invasion in PCa cells...
April 2, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29572775/development-and-application-of-liquid-biopsies-in-metastatic-prostate-cancer
#16
REVIEW
Gareth J Morrison, Amir Goldkorn
PURPOSE OF REVIEW: Metastatic prostate cancer is a lethal and highly heterogeneous malignancy, associated with a broad spectrum of potentially actionable molecular alterations. In the past decade, disease profiling has expanded to include not only traditional tumor tissue, but also liquid biopsies of cells and genetic material circulating in the blood. These liquid biopsies offer a minimally invasive, repeatable source of tumor material for longitudinal disease profiling but also raise new technical and biological challenges...
March 23, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29559283/ki67-is-an-independent-predictor-of-recurrence-in-the-largest-randomized-trial-of-3-radiation-fractionation-schedules-in-localized-prostate-cancer
#17
Anna C Wilkins, Barry Gusterson, Zsolt Szijgyarto, Joanne Haviland, Clare Griffin, Christine Stuttle, Frances Daley, Catherine M Corbishley, David P Dearnaley, Emma Hall, Navita Somaiah
PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a randomized trial of 3 radiation therapy fractionation schedules (74 Gy/37 fractions vs 60 Gy/20 fractions vs 57 Gy/19 fractions). METHODS AND MATERIALS: A matched case-control study design was used; patients with biochemical/clinical failure >2 years after radiation therapy (BCR) were matched 1:1 to patients without recurrence using established prognostic factors (Gleason score, prostate-specific antigen, tumor stage) and fractionation schedule...
February 3, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29555025/genetic-markers-a-landscape-in-prostate-cancer
#18
REVIEW
J M Cozar, I Robles-Fernandez, L J Martinez-Gonzalez, M Pascual-Geler, Alba Rodriguez-Martinez, M J Serrano, J A Lorente, M J Alvarez-Cubero
Prostate cancer (PC) is one of the most common cancers worldwide. The observed variability in progression and responses to the same treatment between patients underlie the genetic heterogeneity of the disease. Nowadays, screening and follow-up biomarkers in PC are still having a deep lack of information, which makes difficult the cancer diagnosis, prognosis and the selection of the most suitable therapies. This is making that currently unnecessary biopsies, over-treatments and hormonoresistances have high rates of prevalence among patients...
January 2018: Mutation Research
https://www.readbyqxmd.com/read/29540440/risk-and-prognosis-of-cancer-after-lower-limb-arterial-thrombosis
#19
Jens Sundbøll, Katalin Veres, Erzsébet Horváth-Puhó, Kasper Adelborg, Henrik Toft Sørensen
Background -Venous thromboembolism can be a presenting symptom of cancer, but the association between lower limb arterial thrombosis and cancer is unknown. We therefore examined cancer risk and prognosis of cancer in patients with lower limb arterial thrombosis. Methods -Using nationwide population-based Danish medical registries, we identified all patients diagnosed with first-time lower limb arterial thrombosis (1994-2013) and followed them until the occurrence of any subsequent cancer diagnosis, emigration, death, or 30 November 2013, whichever came first...
March 14, 2018: Circulation
https://www.readbyqxmd.com/read/29530484/cartilage-oligomeric-matrix-protein-compopathies-and-beyond
#20
REVIEW
Karen L Posey, Francoise Coustry, Jacqueline T Hecht
Cartilage oligomeric matrix protein (COMP) is a large pentameric glycoprotein that interacts with multiple extracellular matrix proteins in cartilage and other tissues. While, COMP is known to play a role in collagen secretion and fibrillogenesis, chondrocyte proliferation and mechanical strength of tendons, the complete range of COMP functions remains to be defined. COMPopathies describe pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED), two skeletal dysplasias caused by autosomal dominant COMP mutations...
March 9, 2018: Matrix Biology: Journal of the International Society for Matrix Biology
keyword
keyword
98461
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"